Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study

OBJECTIVES: Treatment options for patients with unresectable or metastatic salivary gland carcinoma (SGC) are limited. Safety and efficacy of pembrolizumab for SGC expressing programmed death ligand 1 (PD-L1) were explored. MATERIALS AND METHODS: A cohort of patients with advanced, PD-L1-positive SG...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, Roger B., Delord, Jean-Pierre, Doi, Toshihiko, Piha-Paul, Sarina A., Liu, Stephen V., Gilbert, Jill, Algazi, Alain P., Damian, Silvia, Hong, Ruey-Long, Le Tourneau, Christophe, Day, Daphne, Varga, Andrea, Elez, Elena, Wallmark, John, Saraf, Sanatan, Thanigaimani, Pradeep, Cheng, Jonathan, Keam, Bhumsuk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2018
Materias:
Original Articles: Head and Neck
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6211783/
https://www.ncbi.nlm.nih.gov/pubmed/29462123
http://dx.doi.org/10.1097/COC.0000000000000429

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6211783/
https://www.ncbi.nlm.nih.gov/pubmed/29462123
http://dx.doi.org/10.1097/COC.0000000000000429

Ejemplares similares